343 related articles for article (PubMed ID: 29134562)
1. SEOM clinical guidelines for the treatment of metastatic prostate cancer (2017).
Cassinello J; Arranz JÁ; Piulats JM; Sánchez A; Pérez-Valderrama B; Mellado B; Climent MÁ; Olmos D; Carles J; Lázaro M
Clin Transl Oncol; 2018 Jan; 20(1):57-68. PubMed ID: 29134562
[TBL] [Abstract][Full Text] [Related]
2. SEOM clinical guidelines for the treatment of metastatic prostate cancer.
Cassinello J; Climent MA; González del Alba A; Mellado B; Virizuela JA;
Clin Transl Oncol; 2014 Dec; 16(12):1060-6. PubMed ID: 25319721
[TBL] [Abstract][Full Text] [Related]
3. Cabazitaxel for Hormone-Relapsed Metastatic Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Kearns B; Pandor A; Stevenson M; Hamilton J; Chambers D; Clowes M; Graham J; Kumar MS
Pharmacoeconomics; 2017 Apr; 35(4):415-424. PubMed ID: 27770303
[TBL] [Abstract][Full Text] [Related]
4. Metastatic castration resistant prostate cancer: current strategies of management in the Middle East.
Bazarbashi S; Bachour M; Bulbul M; Alotaibi M; Jaloudi M; Jaafar H; Mukherji D; Farah N; Alrubai T; Shamseddine A
Crit Rev Oncol Hematol; 2014 Apr; 90(1):36-48. PubMed ID: 24289901
[TBL] [Abstract][Full Text] [Related]
5. Dutch Economic Value of Radium-223 in Metastatic Castration-Resistant Prostate Cancer.
Peters ML; de Meijer C; Wyndaele D; Noordzij W; Leliveld-Kors AM; van den Bosch J; van den Berg PH; Baka A; Gaultney JG
Appl Health Econ Health Policy; 2018 Feb; 16(1):133-143. PubMed ID: 28866822
[TBL] [Abstract][Full Text] [Related]
6. New and emerging agents for the treatment of castration-resistant prostate cancer.
Higano CS; Crawford ED
Urol Oncol; 2011; 29(6 Suppl):S1-8. PubMed ID: 22074657
[TBL] [Abstract][Full Text] [Related]
7. Current management of advanced and castration resistant prostate cancer.
Gomella LG; Petrylak DP; Shayegan B
Can J Urol; 2014 Apr; 21(2 Supp 1):1-6. PubMed ID: 24775717
[TBL] [Abstract][Full Text] [Related]
8. Expert opinion on chemotherapy use in castration-resistant prostate cancer progressing after docetaxel.
Gallardo E; Arranz JÁ; Maroto JP; León LÁ; Bellmunt J
Crit Rev Oncol Hematol; 2013 Nov; 88(2):357-67. PubMed ID: 23867574
[TBL] [Abstract][Full Text] [Related]
9. New treatment options for patients with metastatic prostate cancer.
Snoeks LL; Ogilvie AC; van Haarst EP; Siegert CE
Neth J Med; 2013; 71(6):290-4. PubMed ID: 23956309
[TBL] [Abstract][Full Text] [Related]
10. Prostate cancer perspectives after chaarted: Optimizing treatment sequence.
Estévez SV; Herranz UA; Calvo OF; Afonso Afonso FJ; Couto LS; Quintela ML; Mateos LL; Maciá Escalante S
Crit Rev Oncol Hematol; 2016 Nov; 107():119-127. PubMed ID: 27823639
[TBL] [Abstract][Full Text] [Related]
11. Novel agents for castration-resistant prostate cancer: Early experience and beyond.
Fujimoto N
Int J Urol; 2016 Feb; 23(2):114-21. PubMed ID: 26311471
[TBL] [Abstract][Full Text] [Related]
12. New agents for the management of castration-resistant prostate cancer.
Cersosimo RJ
Ann Pharmacother; 2012 Nov; 46(11):1518-28. PubMed ID: 23136351
[TBL] [Abstract][Full Text] [Related]
13. Emerging and second line therapies for the management of metastatic castration-resistant prostate cancer: the Australian perspective.
Parente P; Parnis F; Gurney H
Asia Pac J Clin Oncol; 2012 Mar; 8(1):31-42. PubMed ID: 22369442
[TBL] [Abstract][Full Text] [Related]
14. New perspectives in the therapy of castration resistant prostate cancer.
Rescigno P; Buonerba C; Bellmunt J; Sonpavde G; De Placido S; Di Lorenzo G
Curr Drug Targets; 2012 Dec; 13(13):1676-86. PubMed ID: 23043326
[TBL] [Abstract][Full Text] [Related]
15. [Modern treatment of metastatic hormone-sensitive prostate cancer].
Küronya Z; Bíró K; Géczi L; Maráz A
Orv Hetil; 2018 Oct; 159(41):1664-1671. PubMed ID: 30295043
[TBL] [Abstract][Full Text] [Related]
16. Disease and Treatment Characteristics of Men Diagnosed With Metastatic Hormone-Sensitive Prostate Cancer in Real Life: Analysis From a Commercial Claims Database.
Flaig TW; Potluri RC; Ng Y; Todd MB; Mehra M; Higano CS
Clin Genitourin Cancer; 2017 Apr; 15(2):273-279.e1. PubMed ID: 27876504
[TBL] [Abstract][Full Text] [Related]
17. Sequential use of novel therapeutics in advanced prostate cancer following docetaxel chemotherapy.
Omlin A; Pezaro C; Gillessen Sommer S
Ther Adv Urol; 2014 Feb; 6(1):3-14. PubMed ID: 24489604
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic opportunities for castration-resistant prostate cancer patients with bone metastases.
Zustovich F; Fabiani F
Crit Rev Oncol Hematol; 2014 Aug; 91(2):197-209. PubMed ID: 24503416
[TBL] [Abstract][Full Text] [Related]
19. Radium-223 chloride: a new treatment option for metastatic castration-resistant prostate carcinoma.
Pinto A; Cruz P
Drugs R D; 2012 Dec; 12(4):227-33. PubMed ID: 23190319
[TBL] [Abstract][Full Text] [Related]
20. Castration resistant prostate cancer (CRPC): state of the art, perspectives and new challenges.
Massari F; Maines F; Modena A; Brunelli M; Bria E; Artibani W; Martignoni G; Tortora G
Anticancer Agents Med Chem; 2013 Jul; 13(6):872-86. PubMed ID: 23272970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
